



Department of Haematology
University Hospital of Ioannina
St. Niarchou Av, 45500, Ioannina Greece
+302651099656
ehatzim@uoi.gr

ELEFThERIA HATZIMICHAEL, MD, PhD

- Eleftheria Hatzimichael, MD, PhD (born 1975) is a Haematologist, with a strong background and research activities in epigenetics and translational research and currently an **Assistant Professor of Haematology**, in the Faculty of Medicine, School of Health Sciences, University of Ioannina Greece. She graduated from the School of Medicine, University of Ioannina in 1998 and was trained in Haematology at St. Bartholomew's Hospital, Barts and the London Trust, London, UK and the University Hospital of Ioannina, Ioannina, Greece. For her achievements on 2011, she was awarded a prestigious early-career one-year fellowship from the Hellenic Society of Haematology Foundation to work with Dr Isidore Rigoutsos as Visiting Scientist at the Computational Medicine Centre, Jefferson Medical College, Thomas Jefferson University, US, in the field of the non-coding human genome by computational and experimental approaches. She has also received the prestigious Clinical Research Training in Haematology award 2016-2017 by the European Haematology Association, 9-month long unique training and mentoring experience focused on clinical research in Europe, with a global scope. She is the PI of 23 Phase III and IV clinical trials and has served as a subinvestigator in more than 25 phase I-III clinical trials and as a reviewer for more than 27 journals. She is a member of the Associate Editorial Board of the *American Journal of Blood Research* and member of the Editorial Board of *Diseases* (section Oncology) and a member of the Hellenic Society of Haematology, the Greek Myeloma Study Group (GMSG), The Greek (Hellenic) MDS Group, the American Society of Hematology, the European Cancer Research Association and the European Haematology Association. She has more than 120 papers in peer-reviewed journals with an h-index (source Scopus) 30.

Medical education

| | |
|-----------|--|
| 1992-1998 | Medical School of Ioannina, University of Ioannina, Ioannina, Greece |
| Dec 2008 | PhD , Medical School of Ioannina, University of Ioannina, Greece Title of thesis: " <i>Study of the expression and clinical significance of cyclins and the methylation status of cyclin inhibitors in haematological malignancies</i> " |

Education relevant to clinical research

16th ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research,

Flims, Switzerland, 21 - 27 June 2014 (Accepted after assessment)

Clinical Research Training in Haematology 2016-2017, European Haematology Association

Grants

Scholar of the Hellenic Society of Haematology Foundation, 2011-2012

Clinical Research Training in Haematology 2016-2017, European Haematology Association

Appointments and Training

| | |
|----------------------|--|
| Aug 2018 up to now | Assistant Professor of Haematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Greece |
| Dec 2016- Aug 2018 | Consultant Hematologist, Hematology Unit, General Hospital "G. Hatzikosta" |
| Oct 2014-Nov 2016 | Academic Fellow, and Honorary Consultant, University of Ioannina, Ioannina Medical School, Ioannina Greece, Head: Prof E. Briasoulis |
| Mar 2013 - Mar 2014 | Consultant Haematologist Department of Hematology, University Hospital of Ioannina, Greece, Head: Prof E. Briasoulis |
| Jan 2012 - Feb 2013 | Scholar of the Hellenic Society of Haematology, Foundation – Visiting Scientist Computational Medicine Center, Jefferson Medical College, Philadelphia, PA, USA, PI: Prof. Isidore Rigoutsos |
| Feb 2011 - ongoing | Clinical and Translational Research leader, Department of Haematology, University Hospital of Ioannina, Head: Prof. E. Briasoulis |
| Feb 2010- Feb 2011 | Consultant Haematologist Department of Hematology, University Hospital of Ioannina, Greece, Directors: Prof. K.L. Bourantas, Prof E. Briasoulis |
| March 2009 | CCST- Board Certified in Haematology |
| Sep 2005 - Feb 2009 | Trainee in Haematology, Department of Hematology, University Hospital of Ioannina, Greece, Director, Prof. K.L. Bourantas |
| Aug 2004 - Aug 2005 | Clinical Research Fellow in Haematology Oncology, St. Bartholomew's Hospital, London, UK, Clinical Director: Prof T.A. Lister |
| July 2001 - Feb 2004 | Senior House Officer in Internal Medicine, General Hospital "G. Hatzikosta", Ioannina, Greece, Head of the Department: Nikolaos K. Akritidis |
| Dec 1998 - Dec1999 | House Officer in the Health Center of Konitsa, Ioannina, Greece |
| Sep 1998-Sep 1998 | House Officer in "G. Hatzikosta" General Hospital, Ioannina, Greece rotating: Internal Medicine, Cardiology, Surgery |

Publications

124 publications in peer-reviewed journals

Publications 2022

1. Diamantopoulos P, Charakopoulos E, Symeonidis A, Kotsianidis I, Viniou N-A, Pappa V, Pontikoglou Ch, Tsokanas D, Drakos G, Kourakli A, Solomou E, **Hatzimichael E**, Pouli A, Kotsopoulou M, Asmanis E, Dimou M, Panayiotidis P, Papageorgiou S, Vassilopoulos G, Anagnostopoulos A, Vassilakopoulos Th, Papadaki H, Galanopoulos G. Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome. Sci Rep (in press)
2. Georgoulis V, Haidich A-B, Bougioukas K, **Hatzimichael E**. Efficacy and safety of carfilzomib for the treatment of multiple myeloma: an overview of systematic reviews, Crit Rev Hematol Oncol (in press)
3. **Hatzimichael E**, Timotheatou D, Koumpis E, Benetatos L, Makis A. Luspatercept: A New Tool for the Treatment of Anemia Related to β -Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis. Diseases 2022, 10, 85

4. Kyriazopoulou L, Karpathiou G, **Hatzimichael E**, Peoc'h M, Papoudou-Bai A, Kanavaros P. Autophagy and cellular senescence in classical Hodgkin lymphoma. *Pathol Res Pract*. 2022 Jun 1;236:153964. doi: 10.1016/j.prp.2022.153964
5. Karakatsanis SJ, Bouzani M, Symeonidis A, Angelopoulou MK, Papageorgiou SG, Michail M, Gainaru G, Kourti G, Sachanas S, Kalpadakis C, Katodritou E, Leonidopoulou T, Kotsianidis I, Hatzimichael E, Kotsopoulou M, Dimou M, Variamis E, Boutsis D, Kanellias N, Dimopoulou MN, Michali E, Karianakis G, Tsirkinidis P, Vadikolia C, Poziopoulos C, Pigaditou A, Vrakidou E, Economopoulos T, Kyriazopoulou L, Siakantaris MP, Kyrtsolis MC, Anargyrou K, Papaioannou M, Hatjiharissi E, Vervessou E, Tsirogianni M, Palassopoulou M, Stefanoudaki E, Zikos P, Tsirigotis P, Tsourouflis G, Assimakopoulou T, Verrou E, Papadaki H, Lampropoulou P, Dimopoulos MA, Pappa V, Konstantopoulos K, Karmiris T, Roussou P, Panayiotidis P, Pangalis GA, Vassilakopoulos TP; Hellenic Cooperative Lymphoma Group. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. *In Vivo*. 2022 May-Jun;36(3):1302-1315. doi: 10.21873/invivo.12831.
6. Barakos GP, **Hatzimichael E**. Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Diseases*. 2022; 10(2):33. <https://doi.org/10.3390/diseases10020033>
7. Papakonstantinou I, Koumpis E, Fytsili E, Panteli A, Milionis H, Papoudou-Bai A, Kapsali E, **Hatzimichael E**. Leishmaniasis mimicking multiple myeloma. *Int J Lab Hematol* 2022 Feb;44(1):44-46. doi: 10.1111/ijlh.13667.

Full list of Publications at: <http://bit.ly/ehatzimichael>

Citations - As of December 2021

Source Scopus 2921 (excluding self-citations of all authors 2876), **h-index (source Scopus) 29**

Source Google Scholar 4445, **h-index (source Google Scholar) 36, i10-index 70**

Clinical Trials

As Primary Investigator

Phase IV (selected)

1. Real-world evidence of the use of a carfilzomib triplet including an anti-CD38 antibody in patients with multiple myeloma who have received at least one prior therapy, Sponsor Amgen
2. Models of Treatment in Real Conditions and Clinical Outcomes in Unsuitable Patients with AML in Greece Who Receive First Line Systematic Treatment or the Best Supportive Care, the SECURE study
3. Prospective non-invasive study to describe its efficacy and safety as first-line treatment in patients with acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy in routine clinical practice in Greece, the SURVIVE study
4. MiraCLLe Study: An Epidemiological, Prospective, two-year cohort study to Record the True First- and Second-Line Treatment Strategy, in Daily Clinical Practice, Treatment Results in Left-Sided Greece, Quality of Life in Longevity, Sponsor Astra Zeneca
5. P19-568/Concrete: Clinical outcomes of relapse/refractory Chronic Lymphocytic Leukemia (R/R CLL) patients treated with venetoclax in routine clinical settings in Greece, Sponsor: AbbVie Φαρμακευτική ΑΕ
6. Retrospective analysis of clinical outcomes of patients with relapsing / refractory Chronic Lymphocytic Leukemia (R/R CLL) treated with venetoclax: Retrospective analysis from Greece, Sponsor: AbbVie

Phase II-III

1. A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1), Sponsor Abbvie
2. A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
3. A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1), Sponsor Abbvie
4. A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
5. A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1), Sponsor Abbvie
6. A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
7. A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (**CPI 0610-04, MANIFEST-2**)
8. A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
9. A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8), Sponsor GlaxoSmithKline
10. An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of MM with Carfilzomib, Pomalidomide, and Dexamethasone (KPd), Sponsor Amgen
11. A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of IMP in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP), Sponsor: UCB Biopharma SRL
12. Study M20-638: A Phase 3, Multicenter, Randomized, Open-Label Trial of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to Rituximab and Lenalidomide (R2) alone in Subjects with Relapsed or Refractory Follicular Lymphoma, Sponsor: AbbVie
13. Study M20-621: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma Version Number: 1.0, Sponsor: AbbVie
14. PCYC-1143-CA: A Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma, Sponsor: Pharmacyclics
15. ASPER-III-19-1: A phase 3, double-blind, multicentric, randomized, placebo-controlled study to assess the efficacy, safety and tolerability of Itraconazole dry powder for inhalation for the prevention of invasive mould disease in patients with Acute Leukaemia and Neutropaenia, Sponsor: Laboratoires SMB S.A
16. A phase III, randomized, open-label, active-controlled, multicenter study evaluating the efficacy and safety of Crovalimab versus Eculizumab in adult and adolescent patients with paroxysmal nocturnal hemoglobinuria not previously treated with complement inhibitors, Sponsor Hoffmann-La Roche

17. An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd), Sponsor: Amgen
18. A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2), Sponsor: Novartis

As Subinvestigator, Phase II-IV

1. A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Principal Investigator: E. Kapsali
2. Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1), Sponsor: Bristol Mayer Squibb, PI: Prof E. Briasoulis
3. Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM), Sponsor: Bristol Mayer Squibb, PI: Prof E. Briasoulis
4. A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab- chemotherapy (PILLAR 2 Study), Sponsor: Novartis, PI: Prof E. Briasoulis
5. A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload. Sponsor: Novartis, PI: Prof E. Briasoulis
6. «A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension) -ASPIRE: A Study of Eltrombopag In Myelodysplastic SyndRomes and Acute Myeloid Leukemia” Sponsor: GlaxoSmithKline, PI: Prof E. Briasoulis
7. A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anaemic Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS), Sponsor: Amgen, PI: Prof E. Briasoulis
8. A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients ≥ 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy, Sponsor Boehringer Ingelheim, PI: Prof E. Briasoulis
9. GP2013 in the Treatment of Patients with Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL), Sponsor: Novartis, PI: Prof E. Briasoulis
10. A clinical research study evaluating the possibility to suspend the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have been for two different durations on Tasigna with a predefined level of molecular response. Sponsor Novartis, PI: Prof E. Briasoulis
11. A randomized Phase III clinical trial to compare the efficacy and safety of the biosimilar rituximab GP2013 in combination with a standard chemotherapy (CVP) or rituximab MabThera in combination with a standard chemotherapy (CVP), including GP2013/MabThera maintenance therapy in patient with previously untreated advanced stage follicular lymphoma, Sponsor Novartis, PI: Prof E. Briasoulis
12. International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia, Sponsor F. Hoffmann-La Roche Ltd, PI: Prof E. Briasoulis
13. A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL), Sponsor: F. Hoffmann-La Roche Ltd, PI: Prof E. Briasoulis
14. A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera, Sponsor: F. Hoffmann-La Roche Ltd, PI: Prof E. Briasoulis

15. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation, Sponsor: Takeda, PI: Prof E. Briasoulis
16. Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. (ENESTPath), Sponsor: Novartis Pharmaceuticals, PI: Prof E. Briasoulis
17. Phase 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL, Sponsor: Amgen, PI: Prof E. Briasoulis
18. A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma, Sponsor Acerta Pharma BV, Pi. E. Kapsali
19. Μία μη παρεμβατική μελέτη ασφάλειας μετά την έγκριση κυκλοφορίας, για την κατά συνεχή τρόπο επιτήρηση των εκβάσεων ασφαλείας και κύησης σε μία ομάδα εν κινδύνω για Ιδιοπαθή Θρομβοκυτταραιμία (ET) υποκειμένων θεραπειών που εκτίθενται σε Xagrid® σε σύγκριση με άλλες συμβατικές κυτταρομειωτικές θεραπείες», Φορέας: Shire Pharmaceutical Development LTD. Κύριοι Ερευνητές – Primary Investigators (KE-PI): Κ.Α. Μπουραντάς, Ε. Μπριασούλης
20. An observational study of Velcade, Φορέας: Janssen Cilag, KE: Κ.Α. Μπουραντάς, Ε. Μπριασούλης
21. ICL670 broad-spectrum programs in patients with congenital erythrocyte disorders and chronic iron overload due to blood transfusions that cannot be adequately treated with other marketing-approved iron-binding chemicals, Sponsor: Novartis, PI, KL Bourantas
22. CC-5013-PASS 001”: A non interventional observational post authorization safety study of subjects treated with lenalidomide”, Φορέας: Genesis Pharma SA-Gelgene, KE: Κ.Α. Μπουραντάς, Ε. Μπριασούλης
23. Multicenter retrospective non-invasive study recording of treatment data for patients with multiple myeloma treated with lenalidomide (revlimid) in accordance with established clinical practice, Sponsor Genesis Pharma SA-Gelgene, PI KL Bourantas
24. A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy with LEn/Dex in Greek Patients With R/R Multiple Myeloma and the Treatment PatterNs Following Progressive Disease (LEGEND), Sponsor: Genesis Pharma, Pi E Briasoulis
25. Registry Study for Individuals With del 5q Low or Intermediate-1 Risk MDS (PASS MDS del5q), Sponsor: Celgene, PI E. Briasoulis

Member of Scientific Societies

- Hellenic Society of Haematology, American Society of Haematology, European Haematology, Association, European Association for Cancer Research
- Member of EORTC, Member of ELN
- Secretary of the Steering Committee of the Hellenic Myelodysplastic and Bone Marrow Failure Syndromes

Member of Editorial Boards

- American Journal of Blood Research
- Diseases (Section Oncology)

Reviewer in 27 Scientific Journals